Results 71 to 80 of about 243 (91)
Some of the next articles are maybe not open access.

A long-term study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's disease; An Extension 8-year Follow-up Study.

Current Aging Science, 2023
BACKGROUND MLC601 and MLC901 showed neuroprotective and neuroregenerative properties and positive results in the treatment of dementia and cognitive impairment.
H. Pakdaman   +9 more
semanticscholar   +3 more sources

Protocol for Safety and Efficacy of MLC901 (NeuroAiD II) in Patients With Moderate Traumatic Brain Injury: A Randomized Double-Blind Placebo-Controlled Trial (ANDROMEDA).

Neurosurgery, 2023
BACKGROUND Traumatic brain injury (TBI) remains a leading cause of death and disability, affecting approximately 69 million individuals each year worldwide.
Annabell E. Chua   +3 more
semanticscholar   +3 more sources

MLC901 during sleep deprivation rescues fear memory disruption in rats

Naunyn-Schmiedeberg's Archives of Pharmacology, 2019
Several lines of evidence suggest that sleep deprivation disrupts cognitive and emotional abilities and changes the expression of distinctive categories of genes in the brain. In the present study, saline- or MLC901 (a traditional Chinese medicine)-treated male Wistar rats were first submitted to a modified water box (for 24-h sleep deprivation) and ...
M. Nasehi   +4 more
semanticscholar   +3 more sources

The effects of MLC901 on tau phosphorylation

NeuroReport, 2017
Tauopathies are neurodegenerative diseases that are characterized by the presence of hyperphosphorylated tau-containing neurofibrillary tangles (NFTs) in the brain and include Alzheimer's disease and frontotemporal dementia, which lack effective disease-modifying treatments.
W. Lee   +2 more
semanticscholar   +3 more sources

A COMMENTARY UPDATES ON THE USE OF MLC901 (NEUROAIDTM II/NURAIDTM II) IN PATIENTS WITH CEREBRAL VENOUS SINUS THROMBOSIS

National Journal of Neurology
Cerebral venous sinus thrombosis (CVST), which accounts for 0.5% of all strokes, primarily affects younger individuals and results in mild to moderate disability.
A. Arsovska
semanticscholar   +2 more sources

CLINICAL EXPERIENCE OF THERAPEUTIC BENEFIT OF NEUROAID^TM (MLC901) IN PEDIATRICS: REVIEW OF THREE CASES OF SEVERE TRAUMATIC BRAIN INJURY

National Journal of Neurology
Background. Traumatic Brain Injury (TBI) results in acute and chronic sequalae involving structural and functional impairments especially in children. This leads to significant disability, which affects child’s development and adaptive functions. Elderly
G.S. Kho
semanticscholar   +2 more sources

MLC901 in subacute post-stroke recovery in the eastern European population: Preliminary results of a multicentre study

Journal of the Neurological Sciences, 2021
Anita Anisovska   +5 more
semanticscholar   +2 more sources

Safety and efficacy of MLC601/MLC901 (NeuroAiD) amongst patients who sustain severe spinal cord injury (SATURN study)

Journal of the Neurological Sciences, 2021
H. Ohnmar   +7 more
semanticscholar   +2 more sources

A double-blind, placebo-controlled, randomised, multi-centre, phase III study of MLC901 (neuroaid) for the treatment of cognitive impairment after mild traumatic brain injury

Journal of the Neurological Sciences, 2023
P. Pilipenko   +14 more
semanticscholar   +2 more sources

Real-world effectiveness of MLC901 in subjects after brain injuries in the eastern European population: A preliminary result of neuroaid safe treatment (nest) registry

Journal of the Neurological Sciences, 2021
Anita Anisovska   +5 more
semanticscholar   +2 more sources

Home - About - Disclaimer - Privacy